PD-1

[Modern Pathology] In this review, scientists address the state of PD-L1 testing in lung cancer, the role for tumor mutation burden as a predictive biomarker

[European Journal of Cancer] Murine breast cancer cells were grown in both immune-competent and -deficient BALB/c mice, and tumors were irradiated by three fractions of 24 Gy. A PD-1 blockade and a phosphoinositide 3-kinase (PI3K)γδ inhibitor were then administered every other day for two weeks.

[Journal of Nanobiotechnology] The authors exploited atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia.

[Scientific Reports] 42.8% of patients who exhibited significantly higher immunocyte infiltration and enrichment of immune response-associated signatures were subdivided into immune classes.

[Frontiers in Immunology] Scientists found that the proportion of CD3+TIGIT+ T cells was increased in peripheral blood and cancer tissue in colorectal cancer patients when compared with the healthy donors.

[Frontiers in Immunology] Sanguisorbae Radix extract (SRE) effectively inhibited the PD-1/PD-L1 interaction, thereby improving T cell receptor signaling and the NFAT-mediated luciferase activity of T cells. SRE treatment reduced tumor growth in the humanized PD-L1 MC38 cell allograft humanized PD-1 mouse model.